Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services

International Journal of Drug Policy

Volumn 18, Issue 4, 2007, Pages 306-312

  Sylla, Laurie ^a   Bruce, R Douglas ^a   Kamarulzaman, Adeeba ^b   Altice, Frederick L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MALAYSIA   (Malaysia)

Author keywords

AIDS; Health care integration; Health services; HIV; Injection drug use; Prevention; Substance use; Tuberculosis

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; BUPRENORPHINE; COCAINE; METHADONE; METHAMPHETAMINE; OPIATE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVERSE OUTCOME; ARTICLE; CLINICAL EDUCATION; COMMUNITY CARE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; EARLY DIAGNOSIS; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RISK; INTEGRATED HEALTH CARE SYSTEM; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRIORITY JOURNAL; SCALE UP; SCREENING TEST; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; PREVENTIVE HEALTH SERVICES; PRIMARY HEALTH CARE; PROGRAM DEVELOPMENT; SUBSTANCE-RELATED DISORDERS; TUBERCULOSIS, PULMONARY; VULNERABLE POPULATIONS;

EID: 34547146434     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2007.03.001     Document Type: Article

References (54)

1. Abdool-Karim S.S., Abdool-Karim Q., Friedland G., Lalloo U., and El-Sadr W.M. Implementing anti-retroviral therapy in resource-constrained settings: Opportunities and challenges in integrating HIV and tuberculosis care. AIDS 18 7 (2004) 975-979
2. Aceijas C., Stimson G.V., Hickman M., and Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18 17 (2004) 2295-2303
3. Alaei K., Alaei A., and Mansouri D. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis. Eastern Mediterranean Health Journal 8 6 (2002) 754-757
4. Aliyu M.H., and Salihu H.M. Tuberculosis and HIV disease: Two decades of a dual epidemic. Wien Klin Wochenschr 115 19-20 (2003) 685-697
5. Altarac D., and Dansky S.F. Tuberculosis treatment through directly observed therapy in a large multisite methadone maintenance treatment programme: Addressing the public health needs of a high-risk population. Journal of Public Health Management & Practice 1 4 (1995) 40-47
6. Altice F.L., Bruce R.D., Walton M.R., and Buitrago M.I. Adherence to hepatitis B virus vaccination at syringe exchange sites. Journal of Urban Health 82 1 (2005) 151-161
7. Altice F.L., Springer S., Buitrago M., Hunt D.P., and Friedland G.H. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal of Urban Health 80 3 (2003) 416-427
8. Altice F.L., Sullivan L.E., Smith-Rohrberg D., Basu S., Stancliff S., and Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clinical Infectious Diseases 43 Suppl 4 (2006) S178-S183
9. Basu S., Smith-Rohrberg D., Bruce R.D., and Altice F.L. Models for integrating buprenorphine therapy into the primary HIV care setting. Clinical Infectious Diseases 42 5 (2006) 716-721
10. Brassard P., Bruneau J., Schwartzman K., Senecal M., and Menzies D. Yield of tuberculin screening among injection drug users. International Journal of Tuberculosis and Lung Disease 8 8 (2004) 988-993
11. Broadhead R.S., Heckathorn D.D., Altice F.L., van Hulst Y., Carbone M., Friedland G.H., et al. Increasing drug users' adherence to HIV treatment: Results of a peer-driven intervention feasibility study. Social Science & Medicine 55 2 (2002) 235-246
12. Bruce R.D., and Altice F.L. Editorial comment: Why treat three conditions when it is one patient?. AIDS Reader 13 8 (2003) 378-379
13. Bruce R.D., Altice F.L., Gourevitch M., and Friedland G.H. A review of pharmacokinetic drug interactions between opioid agonist therapy and anti-retroviral medications: Implications and management for clinical practice. Journal of Acquired Immune Deficiency Syndromes 41 5 (2006)
14. Bruce R.D., Dvoryak S., Sylla L., and Altice F.L. HIV treatment access and scale-up for delivery for IDU in Ukraine with opiate substitution therapy with buprenorphine-Programme description and policy implications. International Journal of Drug Policy 18 (2007) 326-328
15. Carrieri M.P., Rey D., Loundou A., Lepeu G., Sobel A., Obadia Y., et al. Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug and Alcohol Dependence 72 1 (2003) 13-21
16. Celentano D.D., Galai N., Sethi A.K., Shah N.G., Strathdee S.A., Vlahov D., et al. Time to initiating highly active anti-retroviral therapy among HIV-infected injection drug users. AIDS 15 13 (2001) 1707-1715
17. Celentano D.D., Vlahov D., Cohn S., Shadle V.M., Obasanjo O., and Moore R.D. Self-reported anti-retroviral therapy in injection drug users. JAMA 280 6 (1998) 544-546
18. Coetzee D., Hilderbrand K., Goemaere E., Matthys F., and Boelaert M. Integrating tuberculosis and HIV care in the primary care setting in South Africa. Tropical Medicine and International Health 9 6 (2004) A11-A15
19. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine 163 9 (2003) 1009-1021
20. Currie C.S., Floyd K., Williams B.G., and Dye C. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 5 (2005) 130
21. Dworkin M.S., Adams M.R., Cohn D.L., Davidson A.J., Buskin S., Horwitch C., et al. Factors that complicate the treatment of tuberculosis in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 39 4 (2005) 464-470
22. FitzGerald J.M., Patrick D.M., Strathdee S., Rekart M., Elwood R.K., Schecter M.T., et al. Use of incentives to increase compliance for TB screening in a population of intravenous drug users. Vancouver Injection Drug Use Study Group. International Journal of Tuberculosis and Lung Disease 3 2 (1999) 153-155
23. Foisy M.M., and Akai P.S. Pharmaceutical care for HIV patients on directly observed therapy. Annals of Pharmacotherapy 38 4 (2004) 550-556
24. Grusky O., Liu H., Li X., Swanson A.N., Duan N., Zhu Y., et al. Is voluntary counselling and testing of drug users in China feasible?. International Journal of STD & AIDS 17 5 (2006) 354-355
25. Gunn R.A., Lee M.A., Callahan D.B., Gonzales P., Murray P.J., and Margolis H.S. Integrating hepatitis, STD, and HIV services into a drug rehabilitation programme. American Journal of Preventive Medicine 29 1 (2005) 27-33
26. Hunt, N., Trace, M., & Bewley-Taylor, D. (2005). Reducing drug related harms to health: Overview of the global evidence (No. Four). The Beckley Foundation Drug Policy Programme.
27. Klein, A., Roberts, M., & Trace, M. (2004). Drug policy and the HIV pandemic in Russia and the Ukraine (No. Two). The Beckley Foundation Drug Policy Programme.
28. Kourbatova E.V., Borodulin B.E., Borodulina E.A., del Rio C., Blumberg H.M., and Leonard Jr. M.K. Risk factors for mortality among adult patients with newly diagnosed tuberculosis in Samara, Russia. International Journal of Tuberculosis and Lung Disease 10 11 (2006) 1224-1230
29. Lally M.A., MacNevin R., Sergie Z., Hitt R., DiSpigno M., Cenedella C., et al. A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center. AIDS Patient Care STDS 19 5 (2005) 298-305
30. Lee S.S., Lee K.C., Wan W.Y., and Wong K.H. A urine-based approach to scale up HIV testing in drug users. AIDS 20 9 (2006) 1349-1351
31. Liebman J., Pat Lamberti M., and Altice F. Effectiveness of a mobile medical van in providing screening services for STDs and HIV. Public Health Nursing 19 5 (2002) 345-353
32. Loughlin A., Metsch L., Gardner L., Anderson-Mahoney P., Barrigan M., and Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care 16 4 (2004) 485-500
33. Lucas G.M. Buprenorphine in primary HIV care clinics: A big pill to swallow. Hopkins HIV Report 16 4 (2004) 5-7
34. Lucas G.M., Cheever L.W., Chaisson R.E., and Moore R.D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 27 3 (2001) 251-259
35. McShane H. Co-infection with HIV and TB: Double trouble. International Journal of STD & AIDS 16 2 (2005) 95-100 101 quiz
36. Moore R.D., Keruly J.C., and Chaisson R.E. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. Journal of Acquired Immune Deficiency Syndromes 35 1 (2004) 46-51
37. Mosam A., Cassol E., Page T., Bodasing U., Cassol S., Dawood H., et al. Generic anti-retroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa. AIDS 19 4 (2005) 441-443
38. Mur-Veeman I., Hardy B., Steenbergen M., and Wistow G. Development of integrated care in England and the Netherlands: Managing across public-private boundaries. Health Policy 65 3 (2003) 227-241
39. Narita M., Ashkin D., Hollender E.S., and Pitchenik A.E. Paradoxical worsening of tuberculosis following anti-retroviral therapy in patients with AIDS. American Journal of Respiratory and Critical Care Medicine 158 1 (1998) 157-161
40. Nunn P., Williams B., Floyd K., Dye C., Elzinga G., and Raviglione M. Tuberculosis control in the era of HIV. Nature Reviews Immunology 5 10 (2005) 819-826
41. Ouellet D., Hsu A., Qian J., Lamm J.E., Cavanaugh J.H., Leonard J.M., et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrobial Agents and Chemotherapy 42 12 (1998) 3107-3112
42. Paltiel A.D., Weinstein M.C., Kimmel A.D., Seage III G.R., Losina E., Zhang H., et al. Expanded screening for HIV in the United States-An analysis of cost-effectiveness. The New England Journal of Medicine 352 6 (2005) 586-595
43. Price P., Mathiot N., Krueger R., Stone S., Keane N.M., and French M.A. Immune dysfunction and immune restoration disease in HIV patients given highly active anti-retroviral therapy. Journal of Clinical Virology 22 3 (2001) 279-287
44. Rompalo A.M., Shah N., Mayer K., Schuman P., Klein R.S., Smith D.K., et al. Influence of injection drug use behavior on reported anti-retroviral therapy use among women in the HIV epidemiology research study: On-site versus referral care. Journal of Acquired Immune Deficiency Syndromes 28 1 (2001) 28-34
45. Sharma S.K., Mohan A., and Kadhiravan T. HIV-TB co-infection: Epidemiology, diagnosis & management. The Indian Journal of Medical Research 121 4 (2005) 550-567
46. Smith-Rohrberg D., Mezger J., Walton M., Bruce R.D., and Altice F.L. Impact of enhanced services on virologic outcomes in a directly administered anti-retroviral therapy trial for HIV-infected drug users. Journal of Acquired Immune Deficiency Syndromes 43 1 Suppl. (2006) S48-S53
47. Snyder D.C., Paz E.A., Mohle-Boetani J.C., Fallstad R., Black R.L., and Chin D.P. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. American Journal of Respiratory and Critical Care Medicine 160 1 (1999) 178-185
48. Solomon S., Chakraborty A., and Yepthomi R.D. A review of the HIV epidemic in India. AIDS Education and Prevention: Official Publication of the International Society for AIDS Education 16 3 Suppl. A (2004) 155-169
49. Strathdee S.A., Palepu A., Cornelisse P.G., Yip B., O'Shaughnessy M.V., Montaner J.S., et al. Barriers to use of free anti-retroviral therapy in injection drug users. JAMA 280 6 (1998) 547-549
50. Sullivan L.E., and Fiellin D.A. Buprenorphine: Its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clinical Infectious Diseases 41 6 (2005) 891-896
51. Sullivan L.E., Metzger D.S., Fudala P.J., and Fiellin D.A. Decreasing international HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users. Addiction 100 2 (2005) 150-158
52. Waldrop-Valverde D., Ownby R.L., Wilkie F.L., Mack A., Kumar M., and Metsch L. Neurocognitive aspects of medication adherence in HIV-positive injecting drug users. AIDS Behavior (2006)
53. Walensky R.P., Weinstein M.C., Kimmel A.D., Seage III G.R., Losina E., Sax P.E., et al. Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. The American Journal of Medicine 118 3 (2005) 292-300
54. World Health Organization, United Nations Office on Drugs and Crime. (2005). Policy brief: Anti-retroviral therapy and injecting drug users. Report No. WHO/HIV/2005.06. Geneva: World Health Organization.